Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
16-dihydroxy-5
Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach
3-dimethyl-1-oxobutan-2-yl]carbamate
isolated from Ligusticum chuanxiong Hort
3 h and 5 h after cerebral ischemia and reperfusion
Sitravatinib Catalog No.:M14117-2 16-dihydroxy-5Sitravatinib (MGCD516) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC50s of 1. 5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0. 5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively. Sitravatinib shows potent single agent antitumor efficacy and enhances the activity of PD 1 blockade through promoting an antitumor immune microenvironment. Product information CAS Number:
US$ 55.16
US$ 89.98
US$ 45.99
US$ 10.32
US$ 11.90
US$ 598.38
US$ 15.84
US$ 88.91